Devon S. Conway, MD, reports on key highlights from ECTRIMS 2025, including a phase 3 study showing ocrelizumab significantly reduces relapses in pediatric multiple sclerosis (MS) compared to fingolimod and long-term data for frexalimab demonstrating sustained lesion suppression and high relapse-free rates. Extension data for the Bruton tyrosine kinase inhibitor fenebrutinib revealed ongoing strong MRI activity suppression in relapsing MS, while safety remained favorable.
A trial of clemastine and metformin in optic neuropathy showed promising effects on visual markers but no meaningful clinical improvement over 6 months, suggesting longer studies are needed. Finally, real-world data from Italy indicated that ofatumumab was highly effective in reducing relapses with minimal side effects in patients with relapsing MS.
